A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

Inclusion Criteria:

• SARS-CoV-2 infection confirmed by positive test ≤24 hours before randomization

• COVID-19 symptom onset within 5 days prior to randomization and at least 2signs/symptoms attributable to COVID-19 present and one of at least moderateseverity at Screening

Exclusion Criteria:

• Prior SARS-CoV-2 infection <90 days before enrollment and/or received any COVID-19vaccine dose <90 days before enrollment

• Has one or more conditions associated with high risk for severe COVID-19

• History of hospitalization for the medical treatment of COVID-19

• Currently hospitalized or anticipated need for hospitalization in the clinicalopinion of the investigator

• Known medical history of active liver disease

• Receiving dialysis or have known moderate to severe renal impairment

• Suspected or confirmed concurrent active systemic infection other than COVID-19 thatmay interfere with the evaluation of response to the study drug

• Any comorbidity requiring hospitalization and/or surgery within 7 days before studyentry, or that is considered life threatening within 30 days before study entry

• Known HIV infection with a HIV viral load greater than 400 copies/mL or medicationfor HIV treatment that is prohibited in this study based on medical history within 6months before the screening visit

• History of hypersensitivity or other contraindication to any of the components ofthe study drug

• Has received or is expected to receive pre-exposure prophylactic SARS-CoV-2 mAb

• Has received or is expected to receive convalescent COVID-19 plasma

• Oxygen saturation of ≤93% on room air obtained at rest within 24 hours beforerandomization

• Participating in another interventional clinical study with an investigational agentor device, including those for COVID-19, within 30 days or five half-lives of theagent, whichever is longer, before signing the ICF

• Females who are pregnant or breastfeeding